• Explore /
  • Poster
  • / Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.

Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.

Abstract Video & Slides Poster

Authors

Yohann Loriot

Yohann Loriot

Gustave Roussy, INSERM U981, Université Paris-Saclay, Villejuif, France

Yohann Loriot , Thomas Powles , Miguel Ángel Climent Durán , Srikala S. Sridhar , Joaquim Bellmunt , Daniel Peter Petrylak , Jing Wang , Nuno Matos Costa , Robert J Laliberte , Alessandra Di Pietro , Petros Grivas , Cora N. Sternberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02603432

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 438)

DOI

10.1200/JCO.2021.39.6_suppl.438

Abstract #

438

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Begoña Pérez-Valderrama

First Author: Srikala S. Sridhar

First Author: Srikala S. Sridhar

First Author: Petros Grivas